Search results for "Multivariate Analysi"

showing 10 items of 1084 documents

Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib.

2010

Abstract Introduction. Sorafenib is an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases and has led to a longer median overall survival (OS) time and time to progression (TTP) in patients with advanced hepatocellular carcinoma (HCC). This study was conducted to assess the link between the antitumor efficacy of sorafenib and its early cutaneous side effects in advanced HCC patients. Materials and Methods. All patients received 800 mg daily of sorafenib until progression or unacceptable toxicities. We retrospectively analyzed the incidence of rash and hand–foot skin reactions (HFSR) during the first month of treatment, comparing tumor control (partial response …

MaleCancer ResearchPyridinesSettore MED/06 - Oncologia MedicaKaplan-Meier EstimateGastroenterologySkin Toxicity Hepatocellular CarcinomaSorafenib.Aged 80 and overintegumentary systemIncidence (epidemiology)BenzenesulfonatesLiver NeoplasmsMiddle AgedSorafenibRashhumanitiesOncologyHepatocellular carcinomaToxicityDisease ProgressionFemaleDrug Eruptionsmedicine.symptommedicine.drugAdultNiacinamideSorafenibmedicine.medical_specialtyCarcinoma HepatocellularAntineoplastic AgentsInternal medicinemedicineCarcinomaHumansneoplasmsSurvival analysisAgedRetrospective StudiesSurrogate endpointbusiness.industryPhenylurea CompoundsExanthemamedicine.diseaseSurvival Analysisdigestive system diseasesSurgerybody regionsMultivariate AnalysisHepatobiliarybusiness
researchProduct

Are the recommendations of the French consensus conference on the management of colon cancer followed up?

2006

The aim of this study was to determine how the guidelines published after this conference have spread. Pretherapeutic evaluation and treatment were assessed for all colon cancers diagnosed in a well-defined French population in 2000. Patients were classified either as managed according to the recommendations, or as undermanaged or overmanaged. Outside the emergency context, pretherapeutic work-up was classified as in conformity with the consensus in 48.0% of the cases, as undervalued in 21.9% and as overvalued in 30.1%. The resection rate at 90% was not far from the optimum. Pathological data allowed us to classify nearly all cases according to the tumour node metastasis classification; how…

MaleCancer Researchmedicine.medical_specialtyMultivariate analysisHealth Planning GuidelinesEpidemiologyColorectal cancerConsensus Development Conferences as TopicPopulationColonoscopyContext (language use)Antineoplastic AgentsMedicineHumansNeoplasm MetastasiseducationAgedNeoplasm StagingAged 80 and overeducation.field_of_studyTumour node metastasismedicine.diagnostic_testbusiness.industryGeneral surgeryPublic Health Environmental and Occupational HealthConsensus conferenceGuidelineColonoscopymedicine.diseaseSurgeryOncologyColonic NeoplasmsFemaleFranceGuideline AdherencebusinessFollow-Up StudiesEuropean journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
researchProduct

Personalized Symptom Goals and Patient Global Impression on Clinical Changes in Advanced Cancer Patients.

2018

Abstract Background The aim of this study was to assess the patients’ global impression (PGI) after symptom management, as well as the achievement of personalized symptom goals (PSG). The secondary outcome was to assess related factors. Subjects, Materials, and Methods Advanced cancer patients admitted to palliative care units rated symptom intensity by using the Edmonton Symptom Assessment Score (ESAS) at admission and then after 1 week. For each symptom, patient-reported PGI and PSG, as well as the rate of PSG response, were evaluated. Results Eight hundred seventy-six patients were taken into consideration for this study. A mean of 1.71–2.16 points was necessary to perceive a bit better …

MaleCancer Researchmedicine.medical_specialtyMultivariate analysisPalliative careSymptom assessmentGlobal impression of change03 medical and health sciences0302 clinical medicineIntervention (counseling)Advanced cancerNeoplasmsmedicineOdd ratioHumans030212 general & internal medicineRelated factorsSymptom managementbusiness.industryAdvanced cancer; Global impression of change; Palliative care; Personalized symptom goal; Symptom assessmentAdvanced cancerOncologySymptom Management and Supportive Care030220 oncology & carcinogenesisPersonalized symptom goalPhysical therapyPalliative careFemaleSymptom AssessmentbusinessThe oncologist
researchProduct

Management and prognosis of pancreatic cancer over a 30-year period.

2009

BACKGROUND: The aim of this study was to report on changes in the diagnostic assessment, patterns of care and survival over time for pancreatic cancers. METHODS: A total of 2986 cases of pancreatic cancer from the Digestive Cancer Registry of Burgundy (France) over a 30-year period (1976–2005) were considered. Non-conditional logistic regressions were carried out to identify the factors associated with resection for cure and with the use of chemotherapy. A multivariate relative survival analysis was carried out. RESULTS: Diagnostic procedures have changed. Ultrasonography and computed tomography progressively have become the major diagnostic procedures. There was a slight improvement in sta…

MaleCancer Researchmedicine.medical_specialtyMultivariate analysisPancreatic diseasemedicine.medical_treatmentpancreatic cancerGastroenterologysurvivalstage at diagnosisInternal medicinePancreatic cancerClinical StudiesmedicineHumanscancer registryStage (cooking)Diagnostic Techniques and ProceduresAgedNeoplasm StagingAged 80 and overChemotherapyRelative survivalbusiness.industryCancerMiddle Agedmedicine.diseasePrognosisSurgeryCancer registryPancreatic NeoplasmsLogistic ModelsOncologyMultivariate AnalysisFemalebusinessmanagementBritish journal of cancer
researchProduct

Factors influencing survival after resection of pancreatic cancer. A DNA analysis and a histomorphologic study

1994

BACKGROUND The influence of DNA content on prognosis in stomach cancer has been investigated rarely, and the results are controversial. METHOD The prognostic relevance of the DNA content and histomorphologic parameters was evaluated in 41 patients after resection of pancreatic cancer. RESULTS In the univariate analysis, the DNA content, tumor size, lymph node status, tumor stage, nuclear grade, and type of resection had a statistically significant influence on the prognosis. No association was found between the DNA content and the histomorphologic features. Apart from the operative procedure, the DNA content was the strongest indicator of prognosis in the multivariate analysis. CONCLUSIONS …

MaleCancer Researchmedicine.medical_specialtyPathologyPancreatic diseaseMultivariate analysisGastroenterologyPolyploidyPancreatectomyText miningPancreatic cancerInternal medicinemedicineHumansStomach cancerLymph nodeNeoplasm StagingCell NucleusUnivariate analysisbusiness.industryDNA NeoplasmPrognosismedicine.diseaseDiploidyPancreatic NeoplasmsSurvival Ratemedicine.anatomical_structureOncologyLymphatic MetastasisMultivariate AnalysisLymph Node ExcisionFemalePancreasbusinessFollow-Up StudiesCancer
researchProduct

Classical pediatric Hodgkin lymphoma in very young patients: the Italian experience

2019

Many studies have reported a more favorable outcome in younger patients with Hodgkin lymphoma (HL). The aims of this study were to find an appropriate age cutoff able to identify low-risk children and to describe the natural history of 135 very young patients affected by classic HL (cHL). The best age cutoff was identified at 7 years of age. EFS (p = .0451) and PFS (p = .00921) were significantly better in the group of younger patients. The OS rate at 10 years was 97.0% in the younger group and 92.5% in the older one (p = .0448). However, age was not found to be an independent prognostic factor in multivariate analysis and the better prognosis in younger patients seems to be related to more…

MaleCancer Researchmedicine.medical_specialtyPrognostic factorMultivariate analysisAdolescent03 medical and health sciences0302 clinical medicineInternal medicineOutcome Assessment Health CaremedicineCutoffHumansPublic Health SurveillanceFavorable outcomeAge of OnsetChildchemotherapeutic approachesbusiness.industryAge FactorsDisease ManagementInfantHematologyPrognosisHodgkin DiseaseSurvival AnalysisNatural historypediatricOncologyItalyROC CurveSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA030220 oncology & carcinogenesisChild PreschoolLymphoma and Hodgkin diseaseHodgkin lymphomaDisease characteristicsFemalebusiness030215 immunology
researchProduct

Postponed Is Not Canceled: Role of Craniospinal Radiation Therapy in the Management of Recurrent Infant Medulloblastoma—An Experience From the HIT-RE…

2013

Purpose To evaluate the efficacy of craniospinal irradiation (CSI) in the management of recurrent infant medulloblastoma after surgery and chemotherapy alone. Methods and Materials Seventeen pediatric medulloblastoma patients registered in the HIT-REZ 1997 and 2005 studies underwent CSI as salvage treatment at first recurrence. All patients had achieved complete remission after first-line treatment consisting of surgery and chemotherapy. Eleven patients showed metastatic disease at relapse. Five patients underwent surgery prior to radiation therapy, which resulted in complete resection in 1 case. In 1 patient, complete resection of the residual tumor was performed after CSI. Eleven patients…

MaleCancer Researchmedicine.medical_specialtyTime Factorsmedicine.medical_treatmentMedizinDisease-Free SurvivalCraniospinal IrradiationCohort Studies03 medical and health sciences0302 clinical medicineRecurrencemedicineHumansRadiology Nuclear Medicine and imagingNeoplasm MetastasisChildNeoplasm StagingProportional Hazards ModelsSalvage TherapyMedulloblastomaChemotherapyUnivariate analysisRadiationBrain Neoplasmsbusiness.industryProportional hazards modelInfantRadiotherapy Dosagemedicine.disease3. Good healthSurgeryRadiation therapyTreatment OutcomeOncologyChild Preschool030220 oncology & carcinogenesisMultivariate AnalysisFemaleCranial IrradiationNeoplasm Recurrence LocalbusinessCraniospinal030217 neurology & neurosurgeryProgressive diseaseFollow-Up StudiesMedulloblastomaInternational Journal of Radiation Oncology*Biology*Physics
researchProduct

Malignant germ cell tumors in childhood: results of the first Italian cooperative study "TCG 91".

2003

Background and Aims About 20% of patients with germ cell tumor (GCT) are still resistant to therapy. To investigate which features are present in resistant patients, a multicenter study on GCT in children was undertaken to correlate clinical and laboratory parameters with the outcome. Methods Patients aged less than 16 years, with histologically proven extracranial GCT were included. Results Ninety-five patients (median age 33 months, 45 males) were eligible. The site of the primary tumor was gonadal in 59, extragonadal in 36. The stage was I in 39; II in 5; IIIa (microscopic residue) in 7; IIIb (macroscopic residue) in 16; IIIc (unresectable) in 13; IV in 15. The treatment was surgery alon…

MaleCancer Researchmedicine.medical_treatmentGastroenterologyCohort Studieschemistry.chemical_compoundChildmalignant germ cell tumorsEtoposideOvarian NeoplasmsIfosfamideIncidenceseminomaPrognosisCombined Modality TherapyPrimary tumorChemotherapy regimenTreatment OutcomeItalyOncologyChild PreschoolcarboplatinFemaleGerminomamedicine.drugmedicine.medical_specialtyAdolescentRisk Assessmentrisk factors in malignant germ cellAge Distributioncarboplatin; malignant germ cell tumors; risk factors in malignant germ cell; seminomaTesticular NeoplasmsInternal medicineConfidence IntervalsmedicineHumansSex DistributionSurvival analysisNeoplasm StagingProbabilityRetrospective StudiesChemotherapybusiness.industrySeminomamedicine.diseaseSurvival AnalysisCarboplatinSurgerychemistryMultivariate AnalysisPediatrics Perinatology and Child Healthbusiness
researchProduct

Factors that predict response of patients with hepatitis C virus infection to boceprevir

2012

Background & Aims Little is known about factors associated with a sustained virologic response (SVR) among patients with hepatitis C virus (HCV) infection to treatment with protease inhibitors. Methods Previously untreated patients (from the Serine Protease Inhibitor Therapy 2 [SPRINT-2] trial) and those who did not respond to prior therapy (from the Retreatment with HCV Serine Protease Inhibitor Boceprevir and PegIntron/Rebetol 2 [RESPOND-2] trial) received either a combination of peginterferon and ribavirin for 48 weeks or boceprevir, peginterferon, and ribavirin (triple therapy) after 4 weeks of peginterferon and ribavirin (total treatment duration, 28–48 wk). A good response to interfer…

MaleCirrhosisMESH: Logistic ModelsHepacivirusMESH: Risk AssessmentGastroenterologyPolyethylene GlycolsMESH: Recombinant ProteinsMESH: Genotype0302 clinical medicineOdds RatioProspective StudiesMESH: Treatment OutcomeResponse to Therapy0303 health sciencesMESH: Polymorphism Single NucleotideGastroenterologyvirus diseases3. Good healthMESH: RNA ViralHCVDrug Therapy Combination030211 gastroenterology & hepatologyClinical Trial; Genetic; Prognostic Factors; Response to Therapy; Adult; Antiviral Agents; Biomarkers; Canada; Drug Therapy Combination; Europe; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Interleukins; Logistic Models; Male; Multivariate Analysis; Odds Ratio; Phenotype; Polyethylene Glycols; Polymorphism Single Nucleotide; Proline; Prospective Studies; RNA Viral; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; United States; Viral Load; GastroenterologyViral loadmedicine.medical_specialtyMESH: InterleukinsGenotypeProlineInterferon alpha-2MESH: PhenotypeAntiviral AgentsRisk Assessment03 medical and health sciencesDrug TherapyGeneticMESH: RibavirinMESH: CanadaBoceprevirHumansPolymorphismMESH: ProlineMESH: HumansPrognostic FactorsInterleukinsMESH: AdultOdds ratiomedicine.diseaseUnited Statesdigestive system diseasesClinical trialLogistic ModelschemistryImmunologyMESH: FemaleBiomarkersTime Factorsmedicine.disease_causechemistry.chemical_compoundRisk FactorsInterferonMESH: Risk FactorsMESH: HepacivirusViralSingle NucleotideViral LoadHepatitis CClinical TrialRecombinant ProteinsEuropePhenotypeTreatment OutcomeCombinationRNA ViralFemaleMESH: Interferon-alphaMESH: Viral Loadmedicine.drugAdultMESH: Antiviral AgentsCanadaHepatitis C virusPolymorphism Single NucleotideMESH: Multivariate AnalysisInternal medicineRibavirinmedicineMESH: United States030304 developmental biologyMESH: Hepatitis CHepatologybusiness.industryRibavirinMESH: Time FactorsMESH: Biological MarkersInterferon-alpha[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: Prospective StudiesMESH: MaleMESH: Odds RatioMESH: Drug Therapy CombinationMESH: Polyethylene GlycolsMultivariate AnalysisRNAInterferonsMESH: Europebusiness
researchProduct

Characteristics of patients with hepatitis C virus-related chronic liver diseases just before the era of oral direct-acting antiviral therapy in Italy

2018

Background In 2017, oral direct-acting antiviral (DAA) therapy for chronic hepatitis C virus (HCV) infection became available free of charge for all HCV-RNA-positive patients, irrespective of their fibrosis stage. Aim The aim of this study was to evaluate the characteristics of HCV-related chronic liver disease (CLD) in Italy just before the introduction of DAA therapy. Patients and methods Patients with CLD were enrolled in two national surveys conducted in 2001 and in 2014. The two surveys prospectively enrolled patients aged older than 18 years referring to Italian liver units throughout the country using a similar clinical approach and analytical methods. Results Out of the 12 564 patie…

MaleCirrhosisTime FactorsAdministration OralHepacivirusmedicine.disease_causeChronic liver diseaseSeverity of Illness Index0302 clinical medicineRisk FactorsOdds RatioPrevalenceMedicine030212 general & internal medicineProspective StudiesMultivariate AnalysiGastroenterologyHealth SurveyMiddle AgedViral LoadItalyRNA Viral030211 gastroenterology & hepatologyFemaleHumanAdultmedicine.medical_specialtyLogistic ModelTime FactorGenotypeHepatitis C virusAntiviral AgentsVirus03 medical and health sciencesAge DistributionInternal medicinechronic hepatitis CHumansSex DistributionProtective FactorAgedAntiviral AgentCross-Sectional StudieHepatitis B virusHepaciviruChi-Square DistributionHepatologybusiness.industryRisk Factorchronic liver diseaseBiomarkerOdds ratioHepatitis C AntibodiesHepatitis C ChronicProtective Factorsmedicine.diseaseHealth SurveysConfidence intervaldirect-acting antiviral therapyProspective Studiehepatitis infectionCross-Sectional StudiesLogistic ModelsMultivariate AnalysisEtiologyHepatitis C AntibodiebusinessBiomarkers
researchProduct